Dana Elias
Career history of Dana Elias
Former positions of Dana Elias
| Companies | Position | Start | End |
|---|---|---|---|
| Portman Pharmaceuticals, Inc. | Corporate Officer/Principal | - | - |
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - | - |
| Peptor Ltd | Corporate Officer/Principal | - | - |
Andromeda Biotech Ltd.
 Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel. | Corporate Officer/Principal | 2006-12-31 | - |
Training of Dana Elias
| Weizmann Institute of Science | Doctorate Degree |
Statistics
International
| Israel | 4 |
| Germany | 2 |
| United States | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
| Peptor Ltd | Health Technology |
| Portman Pharmaceuticals, Inc. | |
Andromeda Biotech Ltd.
Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel. | Health Technology |
- Stock Market
- Insiders
- Dana Elias
- Experience
